__NUXT_JSONP__("/drugs/Lapatinib_Ditosylate", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:"Lapatinib",indication:"1 INDICATIONS AND USAGE Lapatinib tablets are indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecetabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor have not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. Lapatinib tablet is a kinase inhibitor indicated in combination with: ( 1 ) capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone-receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor have not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",manufacturer:"Lupin Pharmaceuticals, Inc.",splSetId:"50d0dd0c-7682-43d0-aa1b-ca26e9181aee"},{brand:"TYKERB",indication:"1 INDICATIONS AND USAGE TYKERB Â® is indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. TYKERB is a kinase inhibitor indicated in combination with: ( 1 ) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",manufacturer:"Novartis Pharmaceuticals Corporation",splSetId:"eee37f88-ec6a-4c30-b8aa-e2c71f93088c"}],id:a,nciThesaurus:{casRegistry:"388082-78-8",chebiId:"",chemicalFormula:"C29H26ClFN4O4S.2C7H8O3S.H2O",definition:"The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.",fdaUniiCode:"G873GX646R",identifier:"C66878",preferredName:b,semanticType:"Pharmacologic Substance",subclassOf:["C159156","C2167"],synonyms:["4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl), bis(4-methylbenzenesulfonate), Monohydrate","LAPATINIB DITOSYLATE",b,"Tykerb","lapatinib ditosylate"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLapatinib_Ditosylate",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Lapatinib_Ditosylate","Lapatinib Ditosylate","2021-10-30T13:42:59.743Z")));